The Platform Group delivered strong growth and margin expansion, with a transformational pharma acquisition. We reiterate our BUY rating and € 21 PT.
28 Jan 2026
FY25 on a strong growth path, sig. M&A underway; chg.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
FY25 on a strong growth path, sig. M&A underway; chg.
Platform Group SE & Co. KGaA (TPG0:ETR) | 0 0 0.0%
- Published:
28 Jan 2026 -
Author:
Christian Sandherr -
Pages:
11 -
The Platform Group delivered strong growth and margin expansion, with a transformational pharma acquisition. We reiterate our BUY rating and € 21 PT.